Health Condition 1: H25- Age-related cataract
Conditions
Interventions
Intervention1: SUBCONJUNCTIVAL TRIAMCINOLONE ACETATE: Subconjunctival triamcinolone acetate (20 mg in 0.5 ml) will be given to group A. 0.5 ml of fluid from 40mg/ml vial of triamcinolone acetate (comm
Sponsors
GGSMCH Faridkot
Eligibility
Inclusion criteria
Inclusion criteria: Patients with age related cataract who can be taken up for uncomplicated phacoemulsification surgery (Nuclear opalescence grade 2-5 , cortical grade 2-5, posterior subcapsular grade 2-5 according LOCS III classification
Exclusion criteria
Exclusion criteria: 1 Known allergy to any of the contents of the pharmaceuticals used in the study 2 Posterior polar cataract 3 Uveitis 4 Glaucoma 5 Cystoid macular edema ( clinically significant ) 6 Retinal abnormality causing cystoid macular edema eg diabetes, vein occlusion, subretinal neovascular membrane. 7 Exclusion after enrollment: significant complications to surgery such as posterior capsule rupture, vitreous loss and dislocated lens or cortical material. These surgical complications may cause excessive inflammation and these patients would be excluded from the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Control of inflammation measured by: 1. Anterior chamber inflammation 2. central sub foveal thickness - OCTTimepoint: 6 weeks for each patient; 1.5-2 year for whole study | — |
Secondary
| Measure | Time frame |
|---|---|
| To record the post operative adverse effects including intraocular pressure (IOP), subconjunctival hemorrhage of subconjunctival triamcinolone acetate in comparison to topical steroid eye dropsTimepoint: 6 weeks for each patient; 1.5-2 year for whole study | — |
Countries
India
Contacts
Public ContactHarshita moond
GGSMCH faridkot
Outcome results
None listed